Sex: F
Vaccine: HEP, HEP, VARCEL
Symptoms: Extra dose administered, Inappropriate schedule of product administration, No adverse event
Clinical narrative: No side effects being reported. No additional AE; Patient was not supposed to receive 4th dose of RECOMBIVAX HB.; patient had 2 doses of VARIVAX; 1st dose on 12/18/2007 and 2nd dose on 12/01/2010 and 3rd dose of VARIVAX was given in error on 6/25/2024; Patient had received 3 doses of RECOMBIVAX HB at birth, 2nd dose on 1 /25/2007 (2 months and 3 days), 3rd dose on 6/5/2007 (5 months, 2 weeks). The series for RECOMBIVAX HB were not given as per guidelines for 2nd and 3rd dose; Patient had received 3 doses of RECOMBIVAX HB at birth, 2nd dose on 1 /25/2007 (2 months and 3 days), 3rd dose on 6/5/2007 (5 months, 2 weeks). The series for RECOMBIVAX HB were not given as per guidelines for 2nd and 3rd dose; This spontaneous report was received from a medical assistant and referred to a to a 9-week-old (17-year-old at the reporting time) female patient.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 22-NOV-2006 (the patient was vaccinated with the first dose of hepatitis b vaccine (recombinant) (RECOMBIVAX HB). On 25-JAN-2007, with the second dose of hepatitis b vaccine (recombinant) (RECOMBIVAX HB) (Inappropriate schedule of product administration). On 05-JUN-2007, with the third dose of hepatitis b vaccine (recombinant) (RECOMBIVAX HB) (Inappropriate schedule of product administration), the series for hepatitis b vaccine (recombinant) (RECOMBIVAX HB) were not given as per guidelines for 2nd and 3rd dose of the vaccine (as previously reported). On 18-DEC-2007, the patient was vaccinated with the first dose of varicella virus vaccine live (oka/merck) (VARIVAX) and the second dose on 01-DEC-2010; all vaccines were administered for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided). On 25-JUN-2024, the patient was vaccinated with the fourth dose of hepatitis b vaccine (recombinant) (RECOMBIVAX HB), lot #W038864, (expiration date: 16-JUL-2025) (Extra dose administered) and with the third dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot # X026789, (expiration date: 14-NOV-2025) (Extra dose administered); both vaccines were administered for prophylaxis (strength, dose, and route of administration were not provided). Moreover, the reporter stated that they had a medication error, the patient was not supposed to receive 4th dose of hepatitis b vaccine (recombinant) (RECOMBIVAX HB) and third dose of varicella virus vaccine live (oka/merck) (VARIVAX) which was given in error (as previously reported), the health care professional (HCP) stated that the patient had completed the series and received 4th dose of hepatitis b vaccine (recombinant) (RECOMBIVAX HB) that was not supposed to be administered as well as the 3rd dose of varicella virus vaccine live (oka/merck) (VARIVAX) was not supposed to be administered to the patient either, since varicella virus vaccine live (oka/merck) (VARIVAX) series was already completed for the patient. No side effects were being reported. No other information was provided or known. No additional adverse event (AE) /No product quality complaint (PQC) reported (No adverse event). HCP gave permission to contact her for further information.   Lot # is being requested and will be submitted if received.